AzTrials
AzTrials

Tourette SyndromeBioTicNCT06909656

Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome

A study testing Multimodal electrophysiological recordings in people with Tourette Syndrome, run by University Hospital, Bordeaux at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by the occurrence of involuntary movements (motor tics) and vocalizations (phonic tics). The onset of TS is usually in childhood, and the prevalence of TS is estimated between 0.3 and 0.9% before the age of 18, decreasing progressively after… Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
Tourette Syndrome
What is being tested?
Multimodal electrophysiological recordings
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteFrance
Study dates
17 Feb 2025to 17 Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Patient at least 16 years old.
  • Disabling and drug-resistant Tourette's syndrome.
  • Receiving deep brain stimulation treatment with implantation of the PERCEPT™ Device as part of their medical management.
  • Normal brain MRI.
  • Subject affiliated or beneficiary of a social security system.
  • Free and informed consent of the patient and, for minors, of the minor and at least one parental authority.

Who cannot join

  • Major depressive syndrome (Beck Depression Inventory (BDI-II) > 20).
  • MRI showing significant brain atrophy or significant hyperintensities.
  • Pregnant or nursing mothers.
  • Person unable to give personal consent.
  • Person subject to a legal protection measure (curatorship, guardianship) or placed under court protection.
  • Patient included in another research protocol with an interdiction of participation to another research or in an exclusion period

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • CHU de Bordeaux

    Bordeaux, 33076

    Edouard COURTIN, Dr, 05 57 82 12 42, edouard.courtin@chu-bordeaux.fr

    Recruiting

Other trials in France

About this study

Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by the occurrence of involuntary movements (motor tics) and vocalizations (phonic tics). The onset of TS is usually in childhood, and the prevalence of TS is estimated between 0.3 and 0.9% before the age of 18, decreasing progressively after that age. Most patients also suffer from associated psychiatric comorbidities (ADHD, OCD, mood disorders). Although the cause of TS remains unknown, the preferred hypothesis is the interaction of predisposing genetic factors and precipitating environmental factors (perinatal accidents, infectious diseases). From a pathophysiological point of view, it is widely demonstrated by structural, electrophysiological studies, functional neuroimaging, as well as by different animal models, that dysfunctions of the cortico-striato-pallido-thalamo-cortical loops (responsible for the regulation of movements, cognitive processes, and emotions) play a major role in the genesis of tics. Deep brain stimulation (DBS) treatment can be proposed as an invasive therapy in patients with severe TS resistant to usual treatments (psychotherapy, pharmacological treatments). In a well-selected population of drug-resistant patients, DBS allows an estimated overall improvement of 30 to 50% in the YGTSS score. The deep brain stimulation method currently used in TS is based on continuous (24/7) and undifferentiated stimulation (fixed electrical intensity). This stimulation paradigm, devoid of adaptability to the patient's symptoms, could be at the origin of undesirable effects (related to the modulation of physiological signals), of a sub-optimal efficiency, or of an unnecessary overuse of the stimulator's capacities (battery depletion). The development of new deep brain stimulation paradigms ("closed-loop stimulation"), allowing the identification of pathological neuronal activity and the dynamic adaptation of stimulation parameters to these neuronal signals, requires reliable and reproducible pathological biomarker, correlated with the occurrence of tics.

However, in TS, electrophysiological abnormalities are still not well characterized, and most of the work published on the subject were based on intraoperative recordings and needs to be confirmed on recordings at a distance from the surgery before its potential use in closed-loop stimulation paradigms. Indeed, during the first weeks after surgery, different factors tend to modify the electrophysiological signals.

Read more

Several questions arise at the end of this healing period:

  • Are these pathological oscillations (distinct from the brain oscillations induced by physiological voluntary movement) still detectable weeks after the surgery?
  • What are the temporal dynamics of these oscillations around a tic?
  • What is the spatial topography of these oscillations within the GPi?
  • Is there a strong inter-individual variability?
  • How are changes in cortical activity associated with these subcortical oscillations?
  • Are the modulations of pallidal activity alone sufficient to predict the occurrence of a tic? Thus, our study aims to define precisely the cortico-subcortical activity concomitant with the occurrence of a tic, and to identify reliable and reproducible biomarker(s) associated with tics in TS.

In order to specify these biomarker(s), their temporal correlation to tic occurrence, their spatial distribution, as well as the dynamics and cortico-subcortical coherence of the identified abnormalities, we propose a prospective study on 10 patients with severe and drug-resistant TS, treated by bi-pallidal deep brain stimulation as part of routine care (no device implantation as part of the research).

An evaluation of pallidal LFP synchronized with a high-resolution video-electroencephalography recording (128 to 256 sensors) will be performed at a distance (M+[3-48]) from surgery, in order to determine the variations in pallidal and electroencephalographic activity surrounding the occurrence of tics. A control condition with voluntary ("tic-like") movement will be carried out in a second time, to distinguish the modifications related to the voluntary movement from those related to the occurrence of a tic. A reconstruction of the electrode positioning will be performed using the LeadDBS pipeline, and individual and group analyses will be performed to specify the mapping of pathological oscillations within the pallidum and throughout the cerebral cortex.

Being tested
Multimodal electrophysiological recordings
Keywords
Tourette Syndrome, Local field potentials, Deep Brain Stimulation
Medical subject headings
Tourette Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multimodal electrophysiological recordingsOther

    Intervention(s): Multimodal electrophysiological recordings (Local field potentials, High-Resolution Electroencephalogram, Electromyogram) coupled with video analysis, in experimental condition, in uncontrolled tic and voluntary ("tic-like") movement.

Study groups in NCT06909656
Study groupRoleWhat they receive
Patient with Tourette's syndromeExperimentalPatient with Tourette's syndrome receiving deep brain stimulation treatment with implantation of the PERCEPT™ device as part of their medical management.
Receives: Other: Multimodal electrophysiological recordings

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Spectral power

    Pallidal spectral power in the 2 clinical conditions (i) Tic [pre-tic-post] and (ii) Voluntary ("tic-like") movement [pre-movement-post] respectively.

    Measured: Inclusion visit

Secondary outcomes (12)
  1. Electrode localization

    Measured: Inclusion visit

  2. Pallidal and cortical spectral power

    Pallidal and cortical spectral power analysis in the 2 clinical conditions (i) Tic and (ii) Voluntary movement ("tic-like").

    Measured: Inclusion visit

  3. Pallidal and cortical time-frequency

    the 2 clinical conditions (i) Tic and (ii) Voluntary movement ("tic-like").

    Measured: Inclusion visit

  4. Cortico-subcortical coherence

    Cortico-subcortical coherence of the recorded oscillations.

    Measured: Inclusion visit

  5. Cortico-subcortical phase synchronization

    Cortico-subcortical phase synchronization of the recorded oscillations.

    Measured: Inclusion visit

  6. Cortico-subcortical phase-amplitude coupling

    Cortico-subcortical phase-amplitude coupling of the recorded oscillations.

    Measured: Inclusion visit

  7. Adult ADHD Self-Report Scale (ASRS) Score

    Used to assess symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, it consists of 18 items.

    Total score of 0 to 14: Low probability of ADHD.

    Total score of 15 to 24: Intermediate probability that the person exhibits symptoms of ADHD.

    Total score of 25 to 36: Suggests a high probability of ADHD.

    Measured: Inclusion visit

  8. Adult ADHD Self-Report Scale (ASRS) Score

    Used to assess symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, it consists of 18 items.

    Total score of 0 to 14: Low probability of ADHD.

    Total score of 15 to 24: Intermediate probability that the person exhibits symptoms of ADHD.

    Total score of 25 to 36: Suggests a high probability of ADHD.

    Measured: One month before inclusion

  9. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score

    Considered as the reference scale for evaluating obsessive-compulsive disorders. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is designed to assess both the types of symptoms and their severity. The Y-BOCS evaluates 10 items, each rated from 0 (no symptoms) to 4 (extreme symptoms).

    The total score ranges as follows:

    0 to 7: Normal

    8 to 15: Mild

    16 to 23: Moderate

    24 to 31: Severe

    32 to 40: Very severe

    Measured: Inclusion visit

  10. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score

    Considered as the reference scale for evaluating obsessive-compulsive disorders. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is designed to assess both the types of symptoms and their severity. The Y-BOCS evaluates 10 items, each rated from 0 (no symptoms) to 4 (extreme symptoms).

    The total score ranges as follows:

    0 to 7: Normal

    8 to 15: Mild

    16 to 23: Moderate

    24 to 31: Severe

    32 to 40: Very severe

    Measured: One month before inclusion

  11. Yale Global Tic Severity Scale (YGTSS) Score

    semi-structured clinical interview scale that is considered the gold standard for assessing the severity of tics in both children and adults. The YGTSS evaluates the number, frequency, intensity, complexity, and distress associated with motor and vocal tics over the past week. Each domain is assessed on a 6-point scale (from 0 to 5), with a separate, more global score for "overall disability" concerning the individual's daily life and activities.

    Five sub-scores can be extracted:

    The total "motor tic" score (from 0 to 25)

    The total "vocal tic" score (from 0 to 25)

    The total "tic" score (sum of the two previous scores)

    The overall disability assessment (one item; from 0 to 50)

    The global severity score (from 0 to 100)

    Measured: Inclusion visit

  12. Yale Global Tic Severity Scale (YGTSS) Score

    semi-structured clinical interview scale that is considered the gold standard for assessing the severity of tics in both children and adults. The YGTSS evaluates the number, frequency, intensity, complexity, and distress associated with motor and vocal tics over the past week. Each domain is assessed on a 6-point scale (from 0 to 5), with a separate, more global score for "overall disability" concerning the individual's daily life and activities.

    Five sub-scores can be extracted:

    The total "motor tic" score (from 0 to 25)

    The total "vocal tic" score (from 0 to 25)

    The total "tic" score (sum of the two previous scores)

    The overall disability assessment (one item; from 0 to 50)

    The global severity score (from 0 to 100)

    Measured: One month before inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Apr 2025
  2. Study start17 Feb 2025
  3. Primary completion17 Feb 2027 (estimated)
  4. Study completion17 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06909656
Sponsor's protocol ID
CHUBX 2023/84
Acronym
BioTic
Status last verified
Apr 2025
First submitted
24 Mar 2025
Last updated
3 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Multimodal electrophysiological recordings in people with Tourette Syndrome, run by University Hospital, Bordeaux at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Edouard COURTIN, Dr (05 57 82 12 42, edouard.courtin@chu-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Spectral power (time frame: Inclusion visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in